ABEO Abeona Therapeutics Inc.

2.71
+0.54  (+25%)
Previous Close 2.17
Open 2.22
Price To Book 1.25
Market Cap 133,645,685
Shares 49,315,751
Volume 1,969,657
Short Ratio
Av. Daily Volume 1,203,825
Stock charts supplied by TradingView

NewsSee all news

  1. Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    Sustained wound healing and favorable safety profile observed at three years post-treatment Durable wound healing in large, disabling, chronic wounds EB-101 associated with long-term molecular expression of Type VII

  2. Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa

    Company to provide additional transport stability data points in response to FDA Clinical Hold LetterCMC clearance for VIITAL™ trial anticipated in Q4 2019Investor conference call today, Monday, September 23 at 09:30

  3. Abeona Therapeutics Announces Strategic Review

    NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies LLC as its financial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 interim data due 2H 2019.
ABO-101
Sanfilippo syndrome type B (MPS IIIB)
Phase 3 trial initiation placed on clinical hold.
EB-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 meeting with FDA 2H 2019 to discuss next steps.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)
Phase 1/2 trial planned. Timing to be announced later in 2019.
ABO-202
CLN1 disease (Infantile Batten disease)

Latest News

  1. Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    Sustained wound healing and favorable safety profile observed at three years post-treatment Durable wound healing in large, disabling, chronic wounds EB-101 associated with long-term molecular expression of Type VII

  2. Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa

    Company to provide additional transport stability data points in response to FDA Clinical Hold LetterCMC clearance for VIITAL™ trial anticipated in Q4 2019Investor conference call today, Monday, September 23 at 09:30

  3. Abeona Therapeutics Announces Strategic Review

    NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies LLC as its financial